RU2019137004A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019137004A3 RU2019137004A3 RU2019137004A RU2019137004A RU2019137004A3 RU 2019137004 A3 RU2019137004 A3 RU 2019137004A3 RU 2019137004 A RU2019137004 A RU 2019137004A RU 2019137004 A RU2019137004 A RU 2019137004A RU 2019137004 A3 RU2019137004 A3 RU 2019137004A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762501696P | 2017-05-04 | 2017-05-04 | |
| US62/501,696 | 2017-05-04 | ||
| USPCT/US2017/048748 | 2017-08-25 | ||
| PCT/US2017/048748 WO2018039642A1 (en) | 2016-08-26 | 2017-08-25 | Compositions and methods thereof |
| TW106129169A TW201815387A (zh) | 2016-08-26 | 2017-08-28 | 組成物及其方法 |
| TW106129169 | 2017-08-28 | ||
| US201862634162P | 2018-02-22 | 2018-02-22 | |
| US62/634,162 | 2018-02-22 | ||
| US201862636099P | 2018-02-27 | 2018-02-27 | |
| US201862635554P | 2018-02-27 | 2018-02-27 | |
| US62/636,099 | 2018-02-27 | ||
| US62/635,554 | 2018-02-27 | ||
| US201862636171P | 2018-02-28 | 2018-02-28 | |
| US62/636,171 | 2018-02-28 | ||
| PCT/US2018/030978 WO2018204713A1 (en) | 2017-05-04 | 2018-05-03 | Targeted drug rescue with novel compositions, combinations, and methods thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| RU2019137004A3 true RU2019137004A3 (enExample) | 2021-06-04 |
| RU2019137004A RU2019137004A (ru) | 2021-06-04 |
| RU2760558C2 RU2760558C2 (ru) | 2021-11-29 |
| RU2760558C9 RU2760558C9 (ru) | 2022-02-22 |
Family
ID=65431106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019137004A RU2760558C9 (ru) | 2017-05-04 | 2018-05-03 | Целевой лекарственный препарат и новые композиции, комбинации на его основе и способы их применения |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3618819A4 (enExample) |
| JP (2) | JP7514078B2 (enExample) |
| KR (2) | KR20200062078A (enExample) |
| CN (1) | CN110831584B (enExample) |
| AU (2) | AU2018261654A1 (enExample) |
| BR (1) | BR112019022902A2 (enExample) |
| CA (2) | CA3138116A1 (enExample) |
| IL (1) | IL270326B2 (enExample) |
| MA (1) | MA49464A (enExample) |
| RU (1) | RU2760558C9 (enExample) |
| TW (1) | TWI787260B (enExample) |
| WO (1) | WO2018204713A1 (enExample) |
| ZA (1) | ZA201908006B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200062078A (ko) * | 2017-05-04 | 2020-06-03 | 익스시바 게엠베하 | 신규 조성물, 조합 및 그의 방법을 갖는 표적 약물 구제 |
| AU2020241611A1 (en) * | 2019-03-18 | 2021-11-04 | Avanir Pharmaceuticals, Inc. | Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine |
| JP7400818B2 (ja) * | 2019-06-06 | 2023-12-19 | Jsr株式会社 | 感放射線性樹脂組成物、レジストパターン形成方法及び化合物 |
| CN115667217A (zh) | 2020-05-19 | 2023-01-31 | 赛本爱尔兰有限公司 | 氘化的色胺衍生物和使用方法 |
| CN116473077B (zh) * | 2023-05-08 | 2025-04-11 | 广东方中高新材料有限公司 | 一种n,n配位的镓配合物抗菌剂的合成和应用 |
| CN116473073A (zh) * | 2023-05-08 | 2023-07-25 | 广东方中高新材料有限公司 | 一种含镓配合物的吡唑醚菌酯增效悬浮制剂及其制备方法 |
| CN119432479B (zh) * | 2023-08-04 | 2025-10-03 | 中国石油天然气股份有限公司 | 柴油机润滑油组合物及其制备方法 |
| CN120987847A (zh) * | 2024-11-29 | 2025-11-21 | 江苏恩华药业股份有限公司 | 一种氢溴酸右美沙芬的制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4241065A (en) * | 1979-07-02 | 1980-12-23 | E. I. Du Pont De Nemours And Company | Fluoro analogs of hydrocodone and oxycodone useful as analgesics, narcotic antagonists or both |
| US4950658A (en) * | 1988-12-06 | 1990-08-21 | Board Of Trustees Of Southern Illinois Univ. | Method of medical treatment of Alzheimer's disease |
| US5891885A (en) | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
| US6207674B1 (en) | 1999-12-22 | 2001-03-27 | Richard A. Smith | Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants |
| US6335371B1 (en) * | 2000-11-28 | 2002-01-01 | Orion Corporation | Method for inducing cognition enhancement |
| TWI326214B (en) | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| US20070099947A1 (en) * | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
| JP2009525343A (ja) | 2006-02-03 | 2009-07-09 | アバニール・ファーマシューティカルズ | 鬱病、不安および神経変性疾患を治療するためのデキストロメトルファンおよびキニジンを含む薬剤組成物 |
| MX370608B (es) * | 2007-05-01 | 2019-12-18 | Concert Pharmaceuticals Inc | Compuestos de morfinano. |
| BRPI0811844A2 (pt) * | 2007-05-21 | 2014-11-18 | Reviva Pharmaceuticals Inc | Composto, e, método para tratar um paciente |
| US8017623B2 (en) * | 2008-07-03 | 2011-09-13 | Trinity Laboratories, Inc. | Dextromethorphan hydrochloride |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| WO2014138669A1 (en) * | 2013-03-07 | 2014-09-12 | Mindlab LLC | Pain medicine combination and uses thereof |
| CA2907357A1 (en) | 2013-03-15 | 2014-09-18 | Kinemed, Inc. | Biomarkers |
| TW202106301A (zh) * | 2014-09-14 | 2021-02-16 | 美商阿瓦尼爾製藥股份有限公司 | 用於治療失智症中躁動行為之包含右旋美索芬(dextromethorphan)化合物及奎尼丁(quinidine)的藥學組成物 |
| AU2017315947B2 (en) * | 2016-08-26 | 2022-12-01 | Exciva GmbH | Compositions and methods thereof |
| KR20200062078A (ko) * | 2017-05-04 | 2020-06-03 | 익스시바 게엠베하 | 신규 조성물, 조합 및 그의 방법을 갖는 표적 약물 구제 |
-
2018
- 2018-05-03 KR KR1020197035796A patent/KR20200062078A/ko not_active Ceased
- 2018-05-03 KR KR1020217033764A patent/KR102444803B1/ko active Active
- 2018-05-03 WO PCT/US2018/030978 patent/WO2018204713A1/en not_active Ceased
- 2018-05-03 EP EP18794381.6A patent/EP3618819A4/en active Pending
- 2018-05-03 CA CA3138116A patent/CA3138116A1/en active Pending
- 2018-05-03 AU AU2018261654A patent/AU2018261654A1/en not_active Abandoned
- 2018-05-03 MA MA049464A patent/MA49464A/fr unknown
- 2018-05-03 CN CN201880037396.3A patent/CN110831584B/zh active Active
- 2018-05-03 CA CA3062452A patent/CA3062452C/en active Active
- 2018-05-03 JP JP2019560216A patent/JP7514078B2/ja active Active
- 2018-05-03 RU RU2019137004A patent/RU2760558C9/ru active
- 2018-05-03 BR BR112019022902A patent/BR112019022902A2/pt not_active Application Discontinuation
- 2018-05-04 TW TW107115320A patent/TWI787260B/zh active
-
2019
- 2019-10-31 IL IL270326A patent/IL270326B2/en unknown
- 2019-12-02 ZA ZA2019/08006A patent/ZA201908006B/en unknown
-
2021
- 2021-08-13 AU AU2021215274A patent/AU2021215274B2/en active Active
-
2023
- 2023-07-21 JP JP2023119151A patent/JP2023143940A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3062452C (en) | 2023-10-24 |
| RU2760558C9 (ru) | 2022-02-22 |
| KR20210130827A (ko) | 2021-11-01 |
| IL270326B2 (en) | 2023-02-01 |
| EP3618819A1 (en) | 2020-03-11 |
| JP2020518617A (ja) | 2020-06-25 |
| MA49464A (fr) | 2020-04-29 |
| EP3618819A4 (en) | 2021-01-20 |
| BR112019022902A2 (pt) | 2020-05-19 |
| IL270326A (enExample) | 2018-05-03 |
| ZA201908006B (en) | 2021-04-28 |
| RU2760558C2 (ru) | 2021-11-29 |
| AU2021215274B2 (en) | 2022-11-03 |
| KR102444803B1 (ko) | 2022-09-19 |
| TW201842902A (zh) | 2018-12-16 |
| KR20200062078A (ko) | 2020-06-03 |
| CA3062452A1 (en) | 2018-11-08 |
| JP2023143940A (ja) | 2023-10-06 |
| WO2018204713A1 (en) | 2018-11-08 |
| IL270326B (en) | 2022-10-01 |
| CN110831584A (zh) | 2020-02-21 |
| CN110831584B (zh) | 2023-03-10 |
| CA3138116A1 (en) | 2018-11-08 |
| TWI787260B (zh) | 2022-12-21 |
| JP7514078B2 (ja) | 2024-07-10 |
| RU2019137004A (ru) | 2021-06-04 |
| AU2021215274A1 (en) | 2021-09-02 |
| AU2018261654A1 (en) | 2019-11-14 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH4A | Reissue of patent specification |